Vaxcyte stock surged after its pneumococcal vaccine passed a key phase 3 test
VAX-31 matched or beat Pfizer's Prevnar 20 and Merck's Capvaxive on nearly all measured strains in the OPUS-1 trial
VAX-31 matched or beat Pfizer's Prevnar 20 and Merck's Capvaxive on nearly all measured strains in the OPUS-1 trial